These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Port M; Glaesener S; Ruf C; Riecke A; Bokemeyer C; Meineke V; Honecker F; Abend M Mol Cancer; 2011 May; 10():52. PubMed ID: 21575166 [TBL] [Abstract][Full Text] [Related]
4. The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something? Ottaviano M; Giunta EF; Rescigno P; Pereira Mestre R; Marandino L; Tortora M; Riccio V; Parola S; Casula M; Paliogiannis P; Cossu A; Vogl UM; Bosso D; Rosanova M; Mazzola B; Daniele B; Palmieri G; Palmieri G Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281219 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours. Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254 [TBL] [Abstract][Full Text] [Related]
6. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053 [TBL] [Abstract][Full Text] [Related]
7. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411 [TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry. Fichtner A; Bohnenberger H; Elakad O; Richter A; Lenz C; Oing C; Ströbel P; Kueffer S; Nettersheim D; Bremmer F World J Urol; 2022 Feb; 40(2):373-383. PubMed ID: 35084545 [TBL] [Abstract][Full Text] [Related]
9. Ploidy of malignant mediastinal germ-cell tumors. Oosterhuis JW; Rammeloo RH; Cornelisse CJ; De Jong B; Dam A; Sleijfer DT Hum Pathol; 1990 Jul; 21(7):729-32. PubMed ID: 2163363 [TBL] [Abstract][Full Text] [Related]
10. Genomic evolution and chemoresistance in germ-cell tumours. Taylor-Weiner A; Zack T; O'Donnell E; Guerriero JL; Bernard B; Reddy A; Han GC; AlDubayan S; Amin-Mansour A; Schumacher SE; Litchfield K; Turnbull C; Gabriel S; Beroukhim R; Getz G; Carter SL; Hirsch MS; Letai A; Sweeney C; Van Allen EM Nature; 2016 Nov; 540(7631):114-118. PubMed ID: 27905446 [TBL] [Abstract][Full Text] [Related]
11. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin‑resistant germ cell tumor models: An exploration of the epithelial‑mesenchymal transition regulator Cardoso IIV; Rosa MN; Moreno DA; Tufi LMB; Ramos LP; Pereira LAB; Silva L; Galvão JMS; Tosi IC; Lengert AVH; Da Cruz MC; Teixeira SA; Reis RM; Lopes LF; Pinto MT Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39392037 [TBL] [Abstract][Full Text] [Related]